Literature DB >> 24942688

The role of type I interferons in intestinal infection, homeostasis, and inflammation.

Hyeseon Cho1, Brian L Kelsall.   

Abstract

Type I interferons are a widely expressed family of effector cytokines that promote innate antiviral and antibacterial immunity. Paradoxically, they can also suppress immune responses by driving production of anti-inflammatory cytokines, and dysregulation of these cytokines can contribute to host-mediated immunopathology and disease progression. Recent studies describe their anti-inflammatory role in intestinal inflammation and the locus containing IFNAR, a heterodimeric receptor for the type I interferons has been identified as a susceptibility region for human inflammatory bowel disease. This review focuses on the role of type I IFNs in the intestine in health and disease and their emerging role as immune modulators. Clear understanding of type I IFN-mediated immune responses may provide avenues for fine-tuning existing IFN treatment for infection and intestinal inflammation. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  enteric microbial infection; intestinal inflammation; type I interferons

Mesh:

Substances:

Year:  2014        PMID: 24942688      PMCID: PMC4551418          DOI: 10.1111/imr.12195

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  250 in total

1.  T-Helper 1 and T-helper 2 cytokine responses in gut-associated lymphoid tissue following enteric reovirus infection.

Authors:  J Y Fan; C S Boyce; C F Cuff
Journal:  Cell Immunol       Date:  1998-08-25       Impact factor: 4.868

2.  Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation.

Authors:  Stefan Schwartz; Maria Vergoulidou; Eckart Schreier; Christoph Loddenkemper; Mark Reinwald; Martin Schmidt-Hieber; Willy A Flegel; Eckhard Thiel; Thomas Schneider
Journal:  Blood       Date:  2011-04-12       Impact factor: 22.113

3.  An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis.

Authors:  S M Madsen; P Schlichting; B Davidsen; O H Nielsen; B Federspiel; P Riis; P Munkholm
Journal:  Am J Gastroenterol       Date:  2001-06       Impact factor: 10.864

4.  Localized delivery of interferon-β by Lactobacillus exacerbates experimental colitis.

Authors:  Adelle P McFarland; Ram Savan; Sagie Wagage; Augustina Addison; Karthika Ramakrishnan; Megan Karwan; Tri Duong; Howard A Young
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

5.  Luminal bacteria recruit CD103+ dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation.

Authors:  Julia Farache; Idan Koren; Idan Milo; Irina Gurevich; Ki-Wook Kim; Ehud Zigmond; Glaucia C Furtado; Sergio A Lira; Guy Shakhar
Journal:  Immunity       Date:  2013-02-07       Impact factor: 31.745

6.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

7.  The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response.

Authors:  Kislay Parvatiyar; Zhiqiang Zhang; Rosane M Teles; Songying Ouyang; Yan Jiang; Shankar S Iyer; Shivam A Zaver; Mirjam Schenk; Shang Zeng; Wenwan Zhong; Zhi-Jie Liu; Robert L Modlin; Yong-jun Liu; Genhong Cheng
Journal:  Nat Immunol       Date:  2012-11-11       Impact factor: 25.606

8.  Norovirus regulation of the innate immune response and apoptosis occurs via the product of the alternative open reading frame 4.

Authors:  Nora McFadden; Dalan Bailey; Guia Carrara; Alicia Benson; Yasmin Chaudhry; Amita Shortland; Jonathan Heeney; Felix Yarovinsky; Peter Simmonds; Andrew Macdonald; Ian Goodfellow
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823

9.  Independent and interdependent immunoregulatory effects of IL-27, IFN-β, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis.

Authors:  Denise C Fitzgerald; Zoë Fonseca-Kelly; Melissa L Cullimore; Pegah Safabakhsh; Christiaan J M Saris; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

10.  Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes.

Authors:  Victoria Auerbuch; Dirk G Brockstedt; Nicole Meyer-Morse; Mary O'Riordan; Daniel A Portnoy
Journal:  J Exp Med       Date:  2004-08-09       Impact factor: 14.307

View more
  33 in total

1.  IFN-τ Alleviates Lipopolysaccharide-Induced Inflammation by Suppressing NF-κB and MAPKs Pathway Activation in Mice.

Authors:  Haichong Wu; Gan Zhao; Kangfeng Jiang; Xiuying Chen; Guangze Rui; Changwei Qiu; Mengyao Guo; Ganzhen Deng
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

2.  Enterovirus A71 Induces Neurological Diseases and Dynamic Variants in Oral Infection of Human SCARB2-Transgenic Weaned Mice.

Authors:  Jing-Yi Lin; Kuo-Feng Weng; Chih-Kuang Chang; Yu-Nong Gong; Guo-Jen Huang; Hui-Lan Lee; Yen-Cheng Chen; Chien-Chih Huang; Jia-Ying Lu; Peng-Nien Huang; Huan-Jung Chiang; Che-Min Chen; Shin-Ru Shih
Journal:  J Virol       Date:  2021-08-11       Impact factor: 5.103

3.  A transmissible γδ intraepithelial lymphocyte hyperproliferative phenotype is associated with the intestinal microbiota and confers protection against acute infection.

Authors:  Luo Jia; Guojun Wu; Sara Alonso; Cuiping Zhao; Alexander Lemenze; Yan Y Lam; Liping Zhao; Karen L Edelblum
Journal:  Mucosal Immunol       Date:  2022-05-19       Impact factor: 8.701

4.  IFN-ε protects primary macrophages against HIV infection.

Authors:  Carley Tasker; Selvakumar Subbian; Pan Gao; Jennifer Couret; Carly Levine; Saleena Ghanny; Patricia Soteropoulos; Xilin Zhao; Nathaniel Landau; Wuyuan Lu; Theresa L Chang
Journal:  JCI Insight       Date:  2016-12-08

5.  Tailored immunity at mucosae.

Authors:  Yasmine Belkaid
Journal:  Immunol Rev       Date:  2014-07       Impact factor: 12.988

6.  Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease.

Authors:  E M Giles; T J Sanders; N E McCarthy; J Lung; M Pathak; T T MacDonald; J O Lindsay; A J Stagg
Journal:  Mucosal Immunol       Date:  2016-05-25       Impact factor: 7.313

7.  The cytosolic sensor STING is required for intestinal homeostasis and control of inflammation.

Authors:  M C C Canesso; L Lemos; T C Neves; F M Marim; T B R Castro; É S Veloso; C P Queiroz; J Ahn; H C Santiago; F S Martins; J Alves-Silva; E Ferreira; D C Cara; A T Vieira; G N Barber; S C Oliveira; A M C Faria
Journal:  Mucosal Immunol       Date:  2017-12-20       Impact factor: 7.313

8.  High-level expression of a novel liver-targeting fusion interferon with preferred Escherichia coli codon preference and its anti-hepatitis B virus activity in vivo.

Authors:  Xuemei Lu; Jie Wang; Xiaobao Jin; Jiayong Zhu
Journal:  BMC Biotechnol       Date:  2015-06-12       Impact factor: 2.563

9.  Expression of suppressor of cytokine signaling 1 (SOCS1) impairs viral clearance and exacerbates lung injury during influenza infection.

Authors:  Keer Sun; Sharon Salmon; Vijaya Kumar Yajjala; Christopher Bauer; Dennis W Metzger
Journal:  PLoS Pathog       Date:  2014-12-11       Impact factor: 6.823

10.  An IFN-STAT Axis Augments Tissue Damage and Inflammation in a Mouse Model of Crohn's Disease.

Authors:  Iris Stolzer; Anja Dressel; Mircea T Chiriac; Markus F Neurath; Claudia Günther
Journal:  Front Med (Lausanne)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.